Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]
The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 721
Referral date 01 July 2014

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Associate Director: Janet Robertson
Communications manager: Alice Law
Project manager:

Bijal Joshi

Technical Advisor: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
26 August 2022 Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
15 January 2018 Suspended. The company have advised that they will not be pursuing a licensing application for ipilimumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
July 2014 Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.

For further information on our processes and methods, please see our CHTE processes and methods manual